1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Rotation's Bioinductive Shoulder Implant Succeeds In Australian Trial

 
• By Reed Miller

The device has 510(k) clearance for a broad tendon-repair indication, but the company is sponsoring clinical trials to further validate the technology, which induces new tissue growth around partially torn rotator cuffs rather than simply mechanically reattaching it.

MT1609_RotationMedicalImplant_1200x675
Rotation's bioinductive implant shown on a model of a shoulder, repairing a rotator cuff • Source: Rotation Medical, Inc.

Rotation Medical Inc.'s highly-porous, bioinductive collagen implant induces new tissue formation and creates an environment conducive to the healing of partial-thickness shoulder rotator cuff tears, new clinical data show.

Results of the study, led by Desmond John Bokor of Macquarie University in Australia, were published in the Muscles, Ligaments and Tendons Journal.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.